

## Original Paper

MA Smit, MD, <sup>1</sup> GW van Pelt, BSc, <sup>1</sup> AGH Roodvoets, MSc, <sup>2</sup> E Meershoek-Klein Kranenburg, MSc, <sup>2</sup> H Putter, MSc, PhD, <sup>3</sup> RAEM Tollenaar, MD, PhD, <sup>1</sup> JHJM van Krieken, MD, PhD, <sup>4</sup> WE Mesker, PhD <sup>1</sup>

<sup>1</sup> Department of surgery, Leiden University Medical Center, <sup>2</sup> Datacenter surgery, Leiden University Medical Center, <sup>3</sup> Department of medical statistics, Leiden University Medical Center, <sup>4</sup> Department of pathology, Radboud University Medical Center.

Corresponding author: WE Mesker – [w.e.mesker@lumc.nl](mailto:w.e.mesker@lumc.nl)

WE Mesker, Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Phone: +31715264005, Fax: +31715266750, Email: [w.e.mesker@lumc.nl](mailto:w.e.mesker@lumc.nl).

## Uniform Noting for International application of the Tumour-stroma ratio as Easy Diagnostic tool: study protocol

*Chemotherapy or not? Practice changing approach for the selection of patients for accurate chemotherapy treatment after colon cancer diagnosis*

### Abstract

**Background:** Colon cancer treatment is dependent on stage at diagnosis. The current TNM (Tumour-Node-Metastasis) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision-making for chemotherapy will result in reducing over- and under-treatment. We developed a new, easy to apply, practice-changing method to select colon cancer patients for adjuvant (chemo)therapy: the tumour-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit from adjuvant (chemo)therapy and from those who will not.

**Objective:** The aim of the study is to add, in addition to the TNM classification, the TSR to current routine pathology evaluation. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicentre study will validate the parameter prospectively.

**Methods:** The study is designed for future implementation of the TSR to the current TNM guidelines, using routinely Haematoxylin and Eosin stained tumour tissue sections.

Part 1. An E-learning module with a quality assessment program in the framework of the European Society of Pathology will be developed. This module will be used to assess the reliability and reproducibility of TSR, conducted by national and international pathologists.

Part 2. Validation of the TSR in a prospective cohort of colon cancer pathological stage II-III patients in a multicentre setting. In total 1500 patients will be included.

**Results:** The results of part 1 will be expected in the first half of 2019. For part 2, the inclusion of patients in the prospective study, which started at the end of 2018, will take 3 years with an additional follow-up of 3 years.

**Conclusions:** The main endpoints of this study are:

Part 1. Instructed (international) pathologists who are able to reliably score TSR, resulting in low intra- and inter-observer variation.

Part 2. Confirmation of significant survival differences for patients with a stroma-high tumour versus patients with a stroma-low tumour. Based on these findings modification in current treatment guidelines will be suggested.

**Trial Registration:** The Netherlands Trial Registry (NTR 7270).

**Keywords:** tumour-stroma ratio; colon cancer; pathology; stroma; observer variation; prospective study

## Introduction

Despite complete resection of the primary tumour and surrounding lymph nodes, colon cancer patients often develop recurrence of disease, caused by remaining micro-metastases. These can be treated with chemotherapy. However, as micro-metastases are difficult to detect, treatment guidelines are usually based on tumour characteristics related to disease progression and survival, such as depth of invasion and lymph node metastasis. The current guidelines advise to give adjuvant chemotherapy to patients with a stage III colon carcinoma and patients with stage II and one or more high risk factors [1]. Only part of the patients who are treated with chemotherapy will actually benefit. Furthermore, there is also substantial under-treatment because twenty-five percent of the stage II patients, who did not receive adjuvant (chemo)therapy, will develop recurrence or metastasis within 5 years [2]. Some patients with stage IIIA receive adjuvant chemotherapy, while in some cases the prognosis is better compared to patients with stage IIB disease [1]. The selection of colon cancer patients for adjuvant treatment should be further improved, to establish an optimal treatment regimen for each patient.

Over the last decade the microenvironment or stromal (i.e. non-epithelial) component of tumours has been studied intensively. There is increasing evidence that the tumour stroma plays an important role in the biological behaviour of tumours, their growth, ability to metastasize, but also their response or resistance to anti-cancer drugs [3-6]. Tumours that are rich in stroma behave in a more aggressive way compared to tumours with little stroma [2,7].

The tumour-stroma ratio (TSR) parameter is based on the amount of stroma within the primary tumour and can be determined, without extra costs, during routine pathology assessment. Using the TSR, stage II/III stroma-high (high-risk) patients can be adequately registered for treatment with chemotherapy whereas for the (elderly) patient with stage III and stroma-low further discussion is needed as to whether adjuvant therapy will benefit these patients. New guidelines for patient management will have consequences for better patient management leading to a more optimal selection for adjuvant chemotherapy with potentially a reduction in costs.

A high stroma percentage (>50%) is an unfavourable prognostic factor. The TSR has been validated in various international studies with high inter-observer agreements [2,7-12]. The TSR was discussed by the TNM Evaluation Committee, the Union for International Cancer Control (UICC), and the College of American Pathologists (CAP). They stated that our observations are important and novel and have potential to be added to the TNM staging algorithm as prognosticator. They advocated validation in a prospective multicentre study and development of consensus agreement and a quality assessment program. This protocol elaborates on this recommendation.

Overall objective: the addition of the TSR to current routine pathology next to the TNM classification for clinical decision-making.

Primary objective for each part of the project:

Part 1. To evaluate and improve the reliability and reproducibility of pathologists specifically instructed for TSR scoring.

Part 2. To confirm the prognostic power of the method to select patients at risk for the development of recurrence of disease resulting in high level evidence for adaptation of guidelines.

## Methods

### Histopathological scoring of the TSR

For the evaluation of the TSR, Haematoxylin and Eosin (H&E) stained sections of the primary colon carcinoma, used in routine pathology to determine the T-stage (i.e. the deepest part of the tumour), are analysed using conventional microscopy. Areas with the largest amount of stroma are selected using a 2.5x or 5x objective. An area where both tumour and stromal tissue are present within this vision-site is selected using a 10x objective. Tumour cells have to be present at all borders of the selected image field. Mucinous tumours, although more difficult, can also be scored; an area containing mucus may be used. However, the volume of mucus should be excluded when determining the TSR. Other challenging cases can be tumours with abundant necrosis and/or muscle tissue in between tumour glands. Necrotic areas or muscle tissue should be avoided in the scoring procedure. It is not necessary to score the TSR at the invasive front, picking a field with as much stroma as possible is more accurate.

Stroma-high is defined as  $>50\%$  stromal area, and stroma-low as  $\leq 50\%$  stromal area in the histological section (Figure 1). This cut-off has been determined a priori with maximum discriminative power [2,7,9]. Even if there is only one image-field with a stroma-high score, this image-field is decisive to categorize the patient as stroma-high.

The scoring protocol is available in an instruction movie on the UNITED study website [13] and in written form published by our group [14].




Figure 1. Examples of stroma-low colon cancer (A) and stroma-high colon cancer (B).

## Study design

Part 1. An E-learning module has been developed with a quality assessment program in the framework of the European Society of Pathology (ESP) External Quality Assessment (EQA) program. Using this module a reliability and reproducibility study on H&E stained tumour tissues will be conducted among national and international pathologists.

Part 2. Validation in a prospective cohort of colon cancer stage II-III patients within this multicentre setting. The inclusion is expected to take 3 years, with a 3 year follow-up period.

## Patient description

In the UNITED study all patients are diagnosed with p-stage II or p-stage III colon cancer. For the E-learning, H&E stained slides of stage II-III colon cancer patients were selected in a retrospective manner. Material was obtained from the archive of the Department of Pathology of the Leiden University Medical Center (LUMC).

## Part 1: The E-learning

An E-learning module has been developed in the framework of the ESP. The software used for the E-learning is PathXL Tutor version 6.1.1.1. (Philips). This is web based software which can be accessed worldwide. Participating pathologists receive specific user credentials for access to the E-learning sets. The workflow is shown in figure 2 and includes an introduction film with the technical instructions. Hereafter, the participating pathologists may start the E-learning by analysing the training set containing 40 cases.




Figure 2. Flowchart for the instruction of participating pathologists using the E-learning module.

TSR scores of participating pathologists will be compared to a reference score (consisting of 3 observers at the LUMC). If a pathologist does not pass a set (inter-observer variability  $\kappa < 0.70$ ), he or

she is asked to re-analyse the set. If need be, the instruction video and protocol can be studied again. If a pathologist passes the set ( $\kappa \geq 0.70$ ), the pathologist is able to continue to the next set of 40 slides. The test set will be repeated after two months, thereafter inter-and intra-observer variability are determined. The pathologists are unaware of any clinical information or previous scoring.

The quality of TSR scoring by the participating pathologists will be monitored on a yearly basis by offering control series.

## Part 2: Validation of the TSR in a prospective study

After finishing the E-learning, the pathologist is well instructed to score TSR in daily routine. To validate the TSR prospectively, a multicentre study is set up. The study aims to include, in the participating centres, a total of 1500 colon cancer patients who have undergone complete curative resection (R0 resection), independent of receiving adjuvant chemotherapy according to actual guidelines.

### Recruitment of patients and consent

Each consecutive eligible patient with a clinical stage I/II/III tumour will be informed about the study by their physician or research nurse. After informed consent, the pathologist is notified that the TSR can be determined. All patients, independent of gender and family history are invited to participate. Medical history is no reason for exclusion, apart from malignancies within 10 years prior to current colon carcinoma.

#### *Patient inclusion criteria*

- Histologically proven colon carcinoma
- Complete curative resection (R0 resection)
- c-Stage I (T1-2, N0, M0), II (T3-4, N0, M0) or III (any T, N1-2, M0)
- Age  $\geq 18$  years
- Written informed consent

#### *Exclusion criteria*

- Neo-adjuvant treatment; this influences the amount of tumour and stroma, by fibrosis formation.
- Any malignancy within 10 years prior to the current colon carcinoma (except for basal cell carcinoma or cervical carcinoma in situ) or any colon carcinoma in history; due to prolonged treatment or metastasis from earlier primary tumours which can influence the current colon carcinoma prognosis. Basal cell carcinoma and cervical carcinoma in situ do not have metastatic capacity.
- Multiple synchronous colon tumours; patients with synchronous tumours are likely to have a worse prognosis and need a different approach for treatment.
- Rectum tumours; these are defined as separate entities. Prognosis and treatment is different compared to colon tumours.

#### *Additional exclusion after surgery*

- p-Stage I or stage IV; p-stage I is excluded since these patients will not receive adjuvant treatment. Stage IV patients are excluded since these patients are palliative treated.
- Deceased within 3 months after surgery; patients who die within 3 months after surgery die most often due to comorbidity or surgical complications.

### Safety reporting and risk analysis

The patient material to be analysed in this study is a conventional H&E stained histological section of the primary tumour, obtained during the routine pathology process. The method is without any additional intervention and the study does not have consequences for the treatment of the patients. Therefore, the safety or health of participating subjects will not be jeopardized in any way by this study. Consequently, no adverse events, serious adverse events or suspected unexpected serious adverse events (AEs, SAEs or SUSARs) will occur due to the study. A data safety monitoring board (DSMB) is not indicated.

### Data storage

The LUMC Datacenter, Department of Surgery, is the Central Datacenter and responsible for supply of electronic Case Report Forms (eCRFs), study database, generation of queries within the database and central monitoring.

Data will be stored in Castor EDC [15]. Castor EDC is a cloud-based Electronic Data Capture platform, easy to use by researchers worldwide and highly secured. Data can be easily captured; therefore data is of high quality and reusable. Data and documents will be stored for at least 15 years.

### Statistical analysis

Statistical analysis will be performed using IBM SPSS Statistics version 23.0 in collaboration with the Department of Medical Statistics of the LUMC.

#### *Part 1*

For the analysis of the inter- and intra-observer variability Cohen's kappa coefficient will be used.

#### *Part 2*

##### Sample size calculation

For the prospective cohort a sample size calculation has been performed for both stages, based on earlier research findings [2,7].

p-Stage II patients: with a Hazard ratio of 2.0, adjusted for TNM, and a known percentage of stroma-high patients in p-stage II of 20-25% [2,7], 114 recurrence events with 90% power are necessary. In order to achieve 114 recurrence events based on an event rate of 0.0575 per year (leading to a 5 years probability of 75% and 3-years recurrence probability of 84.2%) this leads to 722 patients.

p-Stage III patients: with a Hazard ratio of 2.0, adjusted for TNM, and a known percentage of stroma-high patients in stage III of 30-35% [2,7], 97 recurrence events with 90% power are necessary. In order to achieve 97 recurrence events based on an event rate of 0.081 per year (leading to a 5 years probability of 66.7% and 3-years recurrence probability of 78.4%) this leads to 450 patients.

In order to obtain 1172 evaluable p-stage II/III, approximately 1500 (+25%) patients will be registered, as all p-stage I and stage IV patients will be excluded.

### Statistical analysis

Survival analysis will be performed using Kaplan-Meier survival analysis and differences in survival distributions will be tested using Log Rank statistics. The Cox proportional hazard model is used to determine the Hazard Ratio (HR) of explanatory variables for overall and disease free survival (OS and DFS).

OS is defined as the time period between the date of surgery and the date of death from any cause or the date of the last follow-up. DFS is defined as the time between the date of surgery and the date of any recurrence (local, regional or distant metastasis), date of new primary tumour or date of death (any cause). If no event occurs DFS is calculated as the time period until the date of last follow-up.

### Ethical considerations

This project will be conducted according to the Declaration of Helsinki, Fortaleza, Brazil, October 2013.

Since this research plan uses already existing H&E stained sections, conventionally prepared for routine diagnostics, there is no risk for the patient and we expect no problems with the regulatory authorities in the collaborating countries.

The UNITED study protocol has been approved by the Medical Research Ethics Committee (MREC) of the LUMC, study number p17.302. Before inclusion of patients in participating countries, the protocol will be endorsed by the MREC of each participating hospital.

Informed consent will be obtained from each eligible patient in oral and written form prior to surgery.

### Results

#### Part 1

The E-learning started mid-2018 and the first results will be expected in the first half of 2019. The results will be presented within 6 to 12 months after the last pathologist has completed the E-learning module.

#### Part 2

The first patients were included at the end of 2018. In total 1500 patients are needed and the expected inclusion time is about 3 years. A follow-up of 3 years is required. Late 2023 the first results are expected, they will be presented within 12 to 18 months after last follow-up.

### Discussion

The UNITED study has been developed to implement the TSR in routine pathology, in addition to the TNM classification and other known risk factors as extra indicator for medical treatment decision making.

Earlier research validated the prognostic value of TSR in retrospective cohort studies. With the UNITED study we aim to validate the prognostic value of the TSR in a prospective way.

The results of the E-learning will contribute to a standardized method and specifically trained pathologists. With the yearly quality assessments, the quality of the scoring method will be monitored and guaranteed.

Besides the tumour characteristics, as described in the TNM classification, to determine the pathological stage, the microenvironment of the tumour is an important factor as well. The microenvironment of a tumour is a wide spread of different cell types. More tumour characteristics in the microenvironment are studied, like tumour budding [16-21], Immunoscore [22-24] and desmoplastic reaction [19,25,26]. They are all independent prognostic biomarkers for survival [16-26]. Outside the present protocol, we aim to study the relation between the different (microenvironment) biomarkers, to better understand the role of the microenvironment and to further improve patient selection for adjuvant treatment.

Treatment decision making in oncology is a multidisciplinary process where medical oncologists play a pivotal role. These professionals will also be involved by the introduction of the TSR in daily clinical practice.

In conclusion, the UNITED study will, for the first time, evaluate the TSR in a prospective cohort to prove its prognostic value in stage II/III colon cancer. After completion of the UNITED study, the TSR will have the highest level of evidence for a prognostic marker and should be ready to use in the daily practice of all gastroenterology pathologists and also ready to play a role in clinical decision making.

### Acknowledgements

We would like to thank all pathologists from the collaborating centres for participating in the UNITED study.

The UNITED study is granted by The Dutch Cancer Society or ‘KWF Kankerbestrijding’ (project 10174) and the ‘Stichting Fonds Oncologie Holland’.

### Conflicts of Interest

None declared

### Abbreviations

AE	Adverse events
c-stage	Clinical stage
CAP	College of American Pathologists
Castor EDC	Castor Electronic Data Capture
DFS	Disease free survival
DSMB	Data safety monitoring board
eCRF	Electronic Case Report Forms
ESP	European Society of Pathology
EQA	External Quality Assessment
H&E	Haematoxylin and Eosin
HR	Hazard ratio
κ	Kappa
KWF	The Dutch Cancer Society
LUMC	Leiden University Medical Centre
MREC	Medical Research Ethics Committee
OS	Overall survival
p-stage	Pathological stage
SAE	Serious adverse events
SUSAR	Suspected unexpected serious adverse events
TNM	Tumour-Node-Metastasis
TSR	Tumour-stroma ratio
UICC	Union for International Cancer Control
UNITED	Uniform Noting for International application of the Tumour-stroma ratio as Easy Diagnostic tool

### References

1. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D, Group EGW. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24 Suppl 6:vi64-72. PMID: 24078664
2. Mesker WE, Liefers GJ, Junggeburst JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ. Presence of a high amount

- of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. *Cell Oncol.* 2009;31(3):169-78. PMID: 19478385
3. Brown JM. Tumor microenvironment and the response to anticancer therapy. *Cancer Biol Ther.* 2002;1(5):453-8. PMID: 12496469
  4. Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. *Biochem Pharmacol.* 2010;80(5):762-70. PMID: 20417189
  5. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature.* 2006;441(7092):437-43. PMID: 16724055
  6. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. *J Natl Cancer Inst.* 2007;99(19):1441-54. PMID: 17895480
  7. Mesker WE, Junggeburst JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. *Cell Oncol.* 2007;29(5):387-98. PMID: 17726261
  8. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. *Br J Cancer.* 2010;102(10):1519-23. PMID: 20407439
  9. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. *Ann Oncol.* 2013;24(1):179-85. PMID: 22865778
  10. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. *Ann Oncol.* 2014;25(3):644-51. PMID: 24458470
  11. van Pelt GW HT, Bastiaannet E, Kjaer-frifeldt S, van Krieken JHJM, Tollenaar RAEM, Flemming B, Sorensen, Mesker WE. Stroma-high lymph node involvement predicts poor survival more accurately for patients with stage III colon cancer. *J Medical Surgical Pathology.* 2016;2. DOI: 10.4172/2472-4971.1000116
  12. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O'Neill RF, Gray RT, McGready C, Dunne PD, McQuaid S, James JA, Salto-Tellez M, Loughrey MB. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. *Histopathology.* 2017;71(1):12-26. PMID: 28165633
  13. Smit M, van Pelt G, Tollenaar R, Mesker W. Uniform Noting for International application of the Tumour-stroma ratio as Easy Diagnostic Tool (UNITED) study website. <http://watchstroma.com/>. Archived at: <http://www.webcitation.org/784EI3ZGH>.
  14. van Pelt GW, Kjaer-Frifeldt S, van Krieken J, Al Dieri R, Morreau H, Tollenaar R, Sorensen FB, Mesker WE. Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. *Virchows Arch.* 2018;473(4):405-12. PMID: 30030621
  15. Castor EDC. <https://www.castoredc.com/>. Archived at: <http://www.webcitation.org/78A3ksBYx>.
  16. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. *Dis Colon Rectum.* 2008;51(5):568-72. PMID: 18286339
  17. Betge J, Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Vieth M, Langner C. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. *Ann Surg Oncol.* 2012;19(12):3706-12. PMID: 22669453
  18. Betge J, Langner C. Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. *Acta Gastroenterol Belg.* 2011;74(4):516-29. PMID: 22319961
  19. Ueno H, Shinto E, Shimazaki H, Kajiwara Y, Sueyama T, Yamamoto J, Hase K. Histologic categorization of desmoplastic reaction: its relevance to the colorectal cancer microenvironment and prognosis. *Ann Surg Oncol.* 2015;22(5):1504-12. PMID: 25395146
  20. van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. *Br J Cancer.* 2016;115(2):156-63. PMID: 27299960

21. Eriksen AC, Sorensen FB, Lindebjerg J, Hager H, dePont Christensen R, Kjaer-Frifeldt S, Hansen TF. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. *Int J Colorectal Dis.* 2018;33(8):1115-24. PMID:29785462
22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science.* 2006;313(5795):1960-4. PMID: 17008531
23. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. *Curr Opin Immunol.* 2013;25(2):261-7. PMID: 23579076
24. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Borger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grutzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Leonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzalka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet.* 2018;391(10135):2128-39. PMID:29754777
25. Ueno H, Kanemitsu Y, Sekine S, Ishiguro M, Ito E, Hashiguchi Y, Kondo F, Shimazaki H, Mochizuki S, Kajiwara Y, Shinto E, Yamamoto J. Desmoplastic Pattern at the Tumor Front Defines Poor-prognosis Subtypes of Colorectal Cancer. *Am J Surg Pathol.* 2017;41(11):1506-12. PMID: 28877064
26. Ueno H, Sekine S, Oshiro T, Kanemitsu Y, Hamaguchi T, Shida D, Takashima A, Ishiguro M, Ito E, Hashiguchi Y, Kondo F, Shimazaki H, Mochizuki S, Kajiwara Y, Shinto E, Yamamoto J, Shimada Y. Disentangling the prognostic heterogeneity of stage III colorectal cancer through histologic stromal categorization. *Surgery.* 2018;163(4):777-83. PMID: 29162344